Physician profile
Steven D Maynard
NPI 1871601658
$76,669.71
in general payments reported to CMS, 2019-2025
50 companies · $705 in 2025
The $705 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $5,613 · 2021: $5,947 · 2022: $7,365 · 2023: $8,075 · 2024: $22K · 2025: $705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,020 · Travel and Lodging: $4,647 · Food and Beverage: $3,090 · Consulting Fee: $1,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $15,695.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,020.00 |
| Travel and Lodging | $4,646.99 |
| Food and Beverage | $3,090.49 |
| Consulting Fee | $1,095.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $36,780.98 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $22,777.67 | 2019-2022 | |
| Sk Life Science, INC. | $9,045.60 | 2020-2024 | Xcopri |
| Abbvie INC. | $1,467.89 | 2019-2025 | |
| Kyowa Kirin, INC. | $1,238.91 | 2020-2024 | Nourianz |
| Novartis Pharmaceuticals Corporation | $488.64 | 2019-2024 | |
| Supernus Pharmaceuticals, INC. | $487.33 | 2019-2020 | |
| Ucb, INC. | $483.07 | 2019-2025 | Rystiggo, Briviact |
| Genzyme Corporation | $312.93 | 2019-2020 | |
| Mdd US Operations, LLC | $290.29 | 2019-2025 | |
| Emd Serono, INC. | $284.10 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $251.11 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $242.37 | 2019-2021 | |
| Amgen INC. | $234.65 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $155.38 | 2019-2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Maynard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.